Related Experiment Video
Updated: May 13, 2026
10:41
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
microRNA aberrations in Waldenström macroglobulinemia
Antonio Sacco1, Yong Zhang, Patricia Maiso
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Clinical Lymphoma, Myeloma & Leukemia
|March 12, 2013
Summary
Waldenström macroglobulinemia (WM) is a B-cell lymphoma. MicroRNAs (miRNAs), particularly miRNA-155, are crucial in WM development and may offer new therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma.
- Characterized by lymphoplasmacytic cells in bone marrow and monoclonal IgM in circulation.
- WM pathogenesis may involve microRNAs (miRNAs) due to distinct miRNA signatures in tumor cells.
Purpose of the Study:
- To investigate the role of microRNAs (miRNAs) in Waldenström macroglobulinemia (WM) pathogenesis.
- To highlight the significance of miRNA-155 in the biological characteristics of WM.
- To provide a rationale for exploring miRNA-based therapeutic strategies for WM.
Main Methods:
- Analysis of microRNA (miRNA) expression profiles in primary WM tumor cells.
- In vitro and in vivo studies to assess the role of miRNA-155.
- Comparative analysis of WM cells versus normal counterparts.
Main Results:
- Primary WM tumor cells exhibit a unique micro-RNA (miRNA) signature.
- miRNA-155 is identified as a key deregulated miRNA with a pivotal role in WM.
- Evidence supports miRNA-155's involvement in WM's biological characteristics.
Conclusions:
- MicroRNAs (miRNAs) are important in supporting Waldenström macroglobulinemia (WM) pathogenesis.
- miRNA-155 plays a critical role in the disease's biology.
- miRNA-based therapies represent a promising avenue for WM treatment.
